{"id":"vehicle-opthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does not contain any active pharmaceutical ingredients and is used to remove debris, bacteria, or other foreign particles from the eye. This solution is often used after eye surgery or to treat eye irritation.","oneSentence":"Vehicle Ophthalmic Solution is a non-medicated solution used to flush out the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:26.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of dry eye disease"}]},"trialDetails":[{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT02128113","phase":"PHASE2","title":"RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-05-31","conditions":"Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation","enrollment":307},{"nctId":"NCT04674358","phase":"PHASE2, PHASE3","title":"The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2020-11-21","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":329},{"nctId":"NCT03916042","phase":"PHASE2","title":"A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-23","conditions":"Dry Eye","enrollment":206},{"nctId":"NCT06045299","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-09-27","conditions":"Presbyopia, Near Vision, Miosis","enrollment":300},{"nctId":"NCT05753189","phase":"PHASE3","title":"Phase 3 Safety Study for the Treatment of Presbyopia Subjects","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-02-21","conditions":"Presbyopia, Near Vision, Miosis","enrollment":362},{"nctId":"NCT04742283","phase":"PHASE2","title":"Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2020-12-17","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":323},{"nctId":"NCT02121301","phase":"PHASE2","title":"A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2014-04","conditions":"Keratoconjunctivitis Sicca","enrollment":91},{"nctId":"NCT03108664","phase":"PHASE3","title":"HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Sylentis, S.A.","startDate":"2017-05-18","conditions":"Dry Eye Disease","enrollment":330},{"nctId":"NCT03162094","phase":"PHASE1, PHASE2","title":"Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome","status":"UNKNOWN","sponsor":"Avizorex Pharma, S.L.","startDate":"2017-04-03","conditions":"Dry Eye Syndrome","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle Opthalmic Solution","genericName":"Vehicle Opthalmic Solution","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Ophthalmic Solution is a non-medicated solution used to flush out the eye. Used for Treatment of dry eye disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}